MSD's Keytruda is poised to end a 20-year drought in new advances in NHS treatment for early-stage head and neck cancer, after being recommended by reimbursement authority NICE. In final draft ...

Merck & Co.’s first-in-class HIF-2 alpha inhibitor Welireg is touching down in the clear cell renal cell carcinoma (ccRCC) treatment space, notching a Keytruda combination nod that stands to pad the ...

Regulatory clearance includes IV pembrolizumab and subcutaneous pembrolizumab/berahyaluronidase with belzutifan for adjuvant treatment after nephrectomy, including ...

Pfizer and Astellas reckon they have new data for Padcev in bladder cancer that could extend its use into earlier-stage disease, and help the drug meet lofty sales projections. In the ...

Investors have poured billions into the hunt for the next Keytruda. The latest data carries a sobering message: there may be no single successor to Merck’s mega-blockbuster in cancer.

The FDA has approved Rextovy, a new over-the-counter naloxone nasal spray for opioid overdoses. Consumers will be able to purchase the product without a prescription in stores and online. The agency ...